LENZ Therapeutics, Inc. (LENZ) Research & Development (2022 - 2023)
LENZ Therapeutics (LENZ) has disclosed Research & Development for 2 consecutive years, with $19.5 million as the latest value for Q4 2023.
- On a quarterly basis, Research & Development rose 5.82% to $19.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $45.8 million, a 37.14% decrease, with the full-year FY2024 number at $29.8 million, down 49.92% from a year prior.
- Research & Development was $19.5 million for Q4 2023 at LENZ Therapeutics, up from $2.4 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $19.5 million in Q4 2023 to a low of $2.4 million in Q3 2023.